1. When glecaprevir/pibrentasvir ultra-short therapy is enough to eradicate HCV infection
A. Grassi, N. Celli, S. Maccariello, G. Donati, A. Fabbri, G. Ballardini
Rimini, Cattolica (RN)

2. Early hepatic decompensation is the main driver of mortality in patients with hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab or Sorafenib
G. Cabibbo, C. Celsa, S. Battaglia, M. Enea, G. Di Maria, A. Grova, R. Ciccia, G.F. Manfredi, M. Iavarone, A. Vogel, A.G. Singal, M. Reig, D.J. Pinato, C. Cammà
Palermo, London (UK), Novara, Milan, Hannover (Germany), Toronto (Canada), Dallas (USA), Barcelona (Spain), Madrid (Spain)

3. The spleen area affects the performance of the platelet count-based non-invasive tools in predicting hepatic decompensation in MASLD-related advanced chronic liver disease
M. Dallio, M. Romeo, F. Di Nardo, C. Napolitano, P. Vaia, C. Basile, A. Coppola, L.M. Vitale, M. Niosi, A. Federico
Naples

4. The prognostic impact of comorbidities in patients with hepatocellular carcinoma: a multicenter observational study
F. Pelizzaro, E. Pinto, F.P. Russo, M. Gambato, S. Famularo, F. Piscaglia, G. Cabibbo, F. Trevisani, G. Ghittoni, A. Sangiovanni, G. Missale, F. Marra, F.G. Foschi, C. Saitta, G. Svegliati Baroni, . Morisco, E.G. Giannini, S. Boninsegna, M. Di Marco, G. Vidili, F.R. Ponziani, A. Martini, R. Sacco, M.R. Brunetto, A. Mega, F. Azzaroli, D. Magalotti, G. Nardone, D. Sacerdoti, F. Farinati on behalf of the ITA.LI.CA study group
Padua, Pieve Emanuele (MI), Rozzano (MI), Bologna, Palermo, Viterbo, Milan, Parma, Florence, Faenza (RA), Messina, Ancona, Naples, Genoa, Negrar (VR), Seriate (BG), Sassari, Rome, Foggia, Pisa, Bolzano, Verona

5. Workforce reintegration for liver transplant recipients: interdisciplinary assessment of unemployment risk factors
M. Saracco, A. Godono, M. Maci, A.C. Surra, G. Curoso, F. Angelino, C. Arnone, S. Strona, B. Papaleo, S. Sottile, M.V. Picciaiola, P. Boffetta, C. Frascheri, E. Pira, A. Ottobrelli, D. Cocchis, G.M. Saracco, R. Romagnoli, S. Martini
Turin, Bologna

6. Hepatitis delta virus (hdv) replication through hbv integrants in hcc recurrence after liver transplantation
L. Di Marco, N. De Maria, A. Pivetti, A. Colecchia, A. Romanzi, A. Spallanzani, G.  Guaraldi, G. Dolci, G. Ciusa, F. Di Benedetto, P. Magistri, S. Di Sandro, E. Degasperi, M.P. Anolli, P. Lampertico, D. Giosa, D. Lombardo, G. Raimondo, T. Pollicino
Modena, Palermo, Milan, Messina

7. Outcomes and safety of DAA treatment in HCV cirrhotic patients treated with Atezolizumab- Bevacizumab for hepatocellular carcinoma
L. Stella, G. Cabibbo, M. Iavarone, F. Piscaglia, F. Tovoli, F. Marra, C. Mazzarelli, R. Tortora, A. Aghemo, S. De Nicola, S. Bhoori, M. Pallozzi, A. Gasbarrini, L. Cerrito, F.R Ponziani
Rome, Palermo, Milan, Bologna, Florence, Naples

8. AI-Driven Diagnosis: Enhancing HCV-Related Cirrhosis Detection with Multilayer Perceptron Networks
F. Bronte, A. Affronti, F. Gambino, G. Mogavero, M.G. Bavetta, M.R. Barcellona, G. Fusco, S. Esposito, A.V. Gaddi, E. Aragona
Palermo, Parma, Bologna

9. Evidence of durable response to bepirovirsen in B-Clear On-NA responders: B-Sure second report
S.G. Lim, T. Asselah, G.I. Diaconescu, A. Gadano, N.U. Gankina, S. Marciano, G. Rizzardini, T. Stepanova, H.J. Yim, M.F. Yuen, A. Walker, C. Macfarlane, S. Corson, J. Dong, H. Plein, A. Delli Carri, G. Quinn, S. Kendrick, M. Paff, D. Theodore, R. Elston
Singapore, Clichy (France), Craiova (Romania), Buenos Aires (Argentina), Krasnojarsk (Russian Federation), Milan, Moscow (Russian Federation), Ansan (Republic of Korea), Hong Kong (China), Brentford (UK), Waltham (USA), Glasgow (UK), Shanghai (China), Verona, Hertfordshire (UK), Collegeville (USA), Durham (USA)

10. Analysis of HBV genotype association to bepirovirsen treatment response in patients with chronic HBV infection (Phase 2b B-Clear study)
J. Bouquet, R. Elston, P. Yates, S. You, A.S Youssef, A. Nader, J. Cremer, T. Milano, G. Quinn, F. Campbell, M. Paff, D. Theodore
San Francisco (USA), Hertfordshire (UK), Collegeville (USA), Durham (USA), Verona

11. Bepirovirsen immune mechanism of action may potentiate infected hepatocyte killing: Indirect evidence from B-together peripheral longitudinal biomarker analysis
S. Joshi, J. Freudenberg, J. Singh, L. Felton, S. Dixon, V. Maestrini, M. Paff, D. Theodore, J. Walker
Collegeville (USA), London (UK), Verona, Research Triangle Park (USA), San Francisco (USA)

12. Investigation of linerixibat 40 mg BID for cholestatic pruritus of primary biliary cholangitis (PBC); further data from the Phase 2b GLIMMER study to support the Phase 3 GLISTEN study
J. Fettiplace, B. Swift, S. Zhang, P. Invernizzi, R. von Maltzahn, M. M. McLaughli
London (UK), Research Triangle Park (USA), Collegeville (USA), Monza

13. Mri-based clinical-radiomics analyses of colorectal liver metastases to predict tumor growth patterns by machine learning approach
S. Famularo, E.H. Tran, A. Ammirabile, L. Boldrini, C. Bonifacio, C. Mele, E. Boccia, E. Genco, G. Costa, F. Giuliante, G. Torzilli, L. Viganò, F. Ardito
Rome, Strasbourg (France), Pieve Emanuele (MI), Milan, Bergamo

14. Efficacy and safety of atezolizumab/bevacizumab for hepatocellular carcinoma in a real-life prospective cohort: A 2024 update
B. Stefanini, M. Iavarone, F. Marra, G. Cabibbo, C. Vivaldi, A. Palloni, C. Soldà, F.R. Ponziani, G. Tesini, F. Piscaglia, E. Alimenti, C. Campani, C. Celsa, G. Masi, G. Brandi, S. Lonardi, L. Stella, T. Pressiani, L. Lani, A. Dalbeni, G. Svegliati Baroni, P. Federico, F.G. Foschi, S. De Lorenzo, F. Tovoli on behalf of the ARTE study group
Bologna, Milan, Florence, Palermo, Pisa, Padua, Rome, Rozzano (MI), Verona, Ancona, Naples, Faenza (RA)

15. Management of ascites in elderly patients with cirrhosis: results of an Italian survey
S. Di Cola, L. Lapenna, M. Spigaroli, M. Merli
Rome

16. Prevalence of HBV and HCV infections among at-risk migrant and refugee populations in Italy: 2-year results of the VH-COMSAVAC European project
G. Colucci, E. Sguazzini, R. Damonte, G. Romanò, A. Spada, R. Cassola, P. Lampertico
Milan

17. MPEP combines mGluR5 inhibition and AMPK activation to reduce hepatic steatosis
M. Trucchi, L.G. Di Pasqua, F. Protopapa, S. Lotti, A.C. Croce, M. Vairetti, F. Nicoletti, A. Ferrigno
Pavia, Rome, Pozzilli (IS), Pisa

18. Enterobius vermicularis infection mimicking liver malignancy
C. Simoni, J. Testa, L. Maroni, B. Castiglioni
Busto Arsizio (VA), Gallarate (VA)

19. Predictors of esophago-gastric varices and variceal bleeding in patients receiving atezolizumab/bevacizumab for unresectable hepatocellular carcinoma
S. Ascari, R. Chen, M. Iavarone, B. Stefanini, F. Marra, G. Cabibbo, C. Vivaldi, A. Palloni, C. Soldà, F.R. Ponziani, E. Valenzi, F. Ravaioli, E. Franceschini, G. Tosetti, C. Campani, C. Celsa, G. Masi5, G. Brandi, S. Lonardi, L. Stella, T. Pressiani, L. Lani, A. Dalbeni, G. Svegliati Baroni, P. Federico, L. Ielasi, S. De Lorenzo, F. Piscaglia, F. Tovoli
Bologna, Milan, Florence, Palermo, Pisa, Bologna, Padua, Rome, Rozzano (MI), Verona, Ancona, Naples, Faenza (RA)

20. Long-term outcomes after Combined Liver-Kidney Transplantation: a single center experience
F. Leonardi, L. Pasulo, M. Viganò, F. Neri, A. Amaduzzi, A.R. Plati, P.L. Ruggenenti, D. Pinelli, S. Fagiuoli
Bergamo, Milan

21. To re-transplant, or not to re-transplant, that is the question
F. Leonardi, L. Pasulo, M. Triolo, M.G. Luca’, C. Iegri, A. Loglio, M. Viganò, S. Camagni, M. Guizzetti, I. Riva, T.M. Valetti, D. Pinelli, S. Fagiuoli
Bergamo, Milan

22. AI-AD score: a novel Machine Learning-based model for predicting Acute Liver Decompensation progression a prospective observational study
A. Dalbeni, M. Vicardi, M. Bicego, A. Mantovani, F. Cattazzo, M. Bevilacqua, M. Zoncapè, L. De Marco, K. Donadello, L. Alaimo, A. Ruzzenente, V. Paon, D. Ieluzzi, D. Sacerdoti
Verona

23. Statins in patients with advanced hcc treated with atezolizumab/bevacizumab: a propensity score-matched cohort analysis from arte an Italian prospective multicentric dataset
A. Dalbeni, F. Cattazzo, A. Auriemma, F. Tovoli, M. Iavarone, F. Marra, G. Cabibbo, C. Vivaldi, A. Palloni, C. Soldà, M. Vicardi, L.A. Natola, E. Franceschini, M. Bruccoleri, C. Campani, C. Celsa, G. Masi, G. Brandi, S. Lonardi, F.R. Ponziani, L. Rimassa, T. Pressiani, L. Stella, L. Lani, G. Svegliati Baroni, P. Federico, F. Foschi, S. De Lorenzo, D. Sacerdoti
Verona, Bologna, Milan, Florence, Palermo, Pisa, Padua, Rome, Rozzano (MI), Ancona, Naples, Faenza (RA)

24. RuvBL1/2 ATPase activity is required for HSF1-mediated stress response in hepatocellular carcinoma
D. Papini, A. Guida, I. Simeone, F. Vannucci, G. Defazio, S. Polvani, E. Ceni, A. Ficarelli, G. Dragoni, T. Innocenti, L. Picariello, A. Galli, T. Mello
Florence, Siena

25. Features and factors related to intensive care unit admission of cirrhotic patients with Acute-on-Chronic Liver Failure: a single-center observational study
L. De Marco, A. Dalbeni, M. Bevilacqua, R. Stupia, F. Cattazzo, K. Donadello, D. Sacerdoti
Belluno, Verona, Desenzano del Garda (BS)

26. The real life use of bulevirtide for treatment of chronic HDV infection: an interim analysis in the PITER cohort
PITER Collaborating Investigators

27. Antinuclear antibodies target unknown autoantigens in porto-sinusoidal vascular disorder (PSVD) without portal hypertension
N. Pugliese, A. Tonutti, N. Isailovic, D. Polverini, A. Ceribelli, S. De Nicola, M. De Santis, C. Selmi, A. Aghemo
Milan, Rozzano (MI)

28. Assessing the diagnostic accuracy of ChatGPT-4 in the histopathological evaluation of liver fibrosis in metabolic dysfunction-associated steatotic liver disease
T. Laohawetwanit, D. Panzeri, R. Akpinar, N. Pugliese, C. De Carlo, V. Belsito, L. Terracciano, A. Aghemo, G. Chirico, D. Inverso, J. Calderaro, L. Sironi, L. Di Tommaso
Milan, Pathum Thani (Thailand), Créteil (France)

29. Fibrate-Oca (FI-OCA) Study a Global snapshot of PBC practice around the Glob
V. Ronca, A. De Vincentis, F. Terracciani,  U. Vespasiani Gentilucci, L. Cristoferi, A. Gerussi, M. Scaravaglio, C. Corpechot, A. Tanaka,  G. Cancado, N. Abbas, K. Olsen, S. Rodriguez-Tajes, M.C. Londono, N. Gatselis, V. Lygoura,  G. Dalekos, E. Lytvyak, A. Montano-Loza, E. Culver, F. Nevens, E. Eikelenboom, A. Van der Meer, E. Zigmond, V. Calvaruso, L. Sierra, R. Barba Bernal, A. Bonder, A. Villamil, X. Verhelst, C. Levy, G. Hirschfield, A. Lleo, P. Trivedi, P. Invernizzi,  B. Hansen, M. Carbone
Pieve Emanuele (MI), Rozzano (MI), Rome, Milan, Paris (France), Tokyo (Japan), Toronto (Canada), Birmingham (UK), Larissa (Greece), Thessaly (Greece), Edmonton (Canada), Oxford (UK), Leuven (Belgium), Rotterdam (The Netherlands), Tel Aviv (Israel), Palermo, Boston (USA), Buenos Aires (Argentina), Ghent (Belgium), Miami (USA)

30. Somatic copy number alterations in circulating cell-free DNA as a predictive biomarker for hepatocellular carcinoma: insights from a proof-of-concept study
E. Pinto, E. Lazzarini, F. Pelizzaro, M. Gambato, L. Santarelli, S. Potente, P. Zanaga, T. Zappitelli, R. Cradin, P. Burra, F. Farinati, C. Romualdi, V. Tosello, S. Indraccolo, F.P. Russo
Padua

31. Prognostic value of a composite biomarker score for predicting overall survival in HCC patients
F. Damone, G.P. Caviglia, P. Colombatto, F. Oliveri, G. Ricco, M. Guariglia, S. Gaia, V. Romagnoli, D. Cavallone, E. Rolle, P. Carucci, F. Bonino, M.R. Brunetto
Pisa, Turin, Rome

32. Creatinine as a predictor of clinical events in Metabolic Dysfunction-Associated Steatotic Liver Disease
G. Di Betto, A. Farina, P. Palumbo, B. Patrizi, R. Righetti, S. Ferrarini, E. Corradini, A. Pietrangelo, E. Buzzetti
Modena

33. The changing epidemiology of patients with HCC receiving a first-line systemic therapy: insights from ARPES and ARTE databases (2008-2024)
L. Lani, F. Piscaglia, G. Zaccherini, A. De Sinno, B. Stefanini, M. Iavarone, F. Marra, G. Cabibbo, C. Vivaldi, A. Palloni, C. Soldà, L. Stella, M. Bruccoleri, C. Campani, C. Celsa, G. Masi, G. Brandi, S. Lonardi, F.R. Ponziani, L. Rimassa, T. Pressiani, A. Dalbeni, G. Svegliati Baroni, P. Federico, L. Ielasi, S. De Lorenzo, P. Caraceni, F. Tovoli
Bologna, Milan, Florence, Palermo, Pisa, Bologna, Padua, Rome, Verona, Ancona, Naples, Faenza (RA) 

34. Multiparametric ultrasound-based algorithm SteatoScore2.0 versus monoparametric Controlled Attenuation Parameter in clinical practice: a comparison study in a monocentric MASLD cohort
G. Petralli, A. Salvati, S. Cappelli, L. Surace, G. Ricco, P. Colombatto, L. De Rosa, F. Faita, M.R. Brunetto
Pisa

35. Activation of AMPK by a novel complex I modulator (CIM) reduces lipid accumulation and mitigates fibrosis in an in vivo model of MASLD
F. Protopapa, A. Ferrigno, M. Trucchi, S. Lotti, M. Vairetti, A.C. Croce, P. Sun, S.G. Kauschke, L.G. Di Pasqua
Pavia, Biberach an der Riss (Germany)  

36. Usefulness of cardiology specialist follow up after liver transplant
E.N. Lynch, M. Tanturli, G. Lubian, A. Curto, S. Petruccelli, T. Innocenti, G. Dragoni, S. Gitto, D. Ghinolfi, A. Galli
Florence, Siena, Pisa

37. Wilson disease: presentation, clinical course and complications in a large cohort of patients attending San Paolo Hospital of Milan
F. Samartin, S. Vavassori, A.L. Crosignani, E. Bertolini, P.M. Battezzati
Milano

38. Quantitative morphometric analysis via artificial intelligence-driven image analysis in autoimmune hepatitis: a multi-center study
G. Cazzaniga, E. Merelli, B. Engel, F. Bolis, A. Marini, E. Nofit, L. Cristoferi, D. Bernasconi, F. Malinverno, R. Vigano, R. Taubert, G. Chiarello, M. Camozzi, F. Pagni, M. Carbone, P. Invernizzi, A. Gerussi
Milan, Monza, Hannover (Germany)

39. Characterization of a cohort of liver transplant patients for HBV and/or HBV/HDV related complications: results of a Campania multicenter study
G. Stornaiuolo, L. Salmoni, A. Russo, D. Angrisani, A. Santonicola, G. Valente, F. Longobardi, F. Morisco, M. Persico, M. Stanzione, C. Sagnelli, M. Pisaturo, N. Coppola
Naples, Salerno, Caserta

40. AI-based estimation of cardiovascular risk in MASLD patients using non-contrast CT imaging and clinical data
A. Cirella, P. Bruno, V. Caputo, P. Palumbo, S.J. Santini, A. Quarta, F. Calimeri, P. Palumbo, E. Di Cesare, C. Balsano
L’Aquila, Rende (CS), Rome, Avezzano (AQ)

41. One-year efficacy and safety of tacrolimus in chronic autoimmune hepatitis
A. Gerussi, A. Curto, E. Nofit, D. Bernasconi, A. Bonfichi, D. D’Amato, O. Falco, M. Scaravaglio, F. Malinverno, L. Cristoferi, M. Carbone, P. Invernizzi
Monza, Florence, Pavia, Turin, Sassari, Milan

42. The use of Controlled Attenuation Parameter for the assessment of treatment response in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease undergoing a lifestyle intervention program
L. Vaira, A. Armandi, C. Rosso, G.P. Caviglia, M. Marano, F. Amato, K. Gjini, M. Guariglia, E. Dileo, I. Goitre, D. Ribaldone, S. Bo, E. Bugianesi
Turin

43. The association between non-invasive tests of liver fibrosis and early diastolic dysfunction in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease
F. Amato, A. Armandi, A. Andreis, M. Bellettini, F. Lorusso, K. Gjini, M. Marano, L. Vaira, C. Rosso, G.P. Caviglia, M. Guariglia, E. Dileo, D. Castagno, G. Alunni, G.M. De Ferrari, E. Bugianesi
Turin

44. Incidence of clinical outcomes in patients with MASLD and long-term follow up: results from a single center cohort study
M. Marano, A. Armandi, G.P. Caviglia, C. Rosso, F. Amato, L. Vaira, K. Gjini, M. Guariglia, E. Dileo, E. Bugianesi
Turin

45. Perception and management of liver enzymes abnormalities among IBD specialists: Insights from an IG-IBD survey
N. Pugliese, C. Bezzio, D. Polverini, S. Festa, F.A. Caprioli, S. Renna, E.V. Savarino, A. Variola, M.C. Fantini, D. Pugliese, F. Macaluso, A. Dal Buono, C. Masetti, R. Gabbiadini, L. Loy, A. Armuzzi, A. Aghemo
Pieve Emanuele (MI), Rozzano (MI), Rome, Milan, Palermo, Padua, Negrar di Valpolicella (VR), Cagliari, Rome

46. Dynopenia predicts mortality in patients with liver cirrhosis and hepatocellular carcinoma
P. Gallo, V. Flagiello, A. De Vincentis, S. Di Cola, F. Terracciani, A. Falcomatà, A. Picardi, U. Vespasiani Gentilucci
Rome

47. Automatic generation of learning material for residential students in Emergency Departments (ED): evaluation of AI-generated flashcards for supporting medical management of gastrointestinal emergencies
A. Fontana, G. Sinatti, S. Cicchinelli, A. Cirella, S. Jr. Santini, V. Caputo, I. Letteri, P. Vittorini, C. Balsano
L’Aquila, Teramo, Rome

48. Large Language Model Agent-Based Framework for automated Treatment Prescription in Patients with Chronic Hepatitis C Virus Infection
M. Giuffrè,S. Kresevic, M. Ajcevic, L. Crocè, D. Shung
New Haven (USA), Trieste

49. Treatment of portal hypertension through transjugular intrahepatic portosystemic shunt (TIPS) in patients with porto-sinusoidal vascular disease (PSVD)
M. Fazio, C. Becchetti, G. Perricone, M. Solcia, F. Morelli, A. Alfonsi, F. Barbosa, P.M. Brambillasca, C. Andriulo, M. Vangeli, C. Mazzarelli, R. Viganò, M. Cucco, A.G. Rampoldi, L.S. Belli, A. Airoldi
Milan

50. Portal Vein Recanalization-Transjugular Intrahepatic Portosystemic Shunt (PVR-TIPS) in patients with anatomical portal contraindication to liver transplantation: feasibility and clinical implication
C. Becchetti, G. Perricone, E. Motto, F. Bolis, F. Barbosa, A. Alfonsi, F. Morelli, L. Centonze, R. De Carlis, E. Roselli, A. Vanzulli, G. Monti, L.S Belli, A. Airoldi, L. De Carlis, A. Lauterio, M. Solcia
Milan, Monza

51. Strategies to enhance Natural Killer cell response in Hepatocellular Carcinoma: The role of TGFβ in NK-Cells (dys)function and plasticity
V. Reverberi, A. Montali, A. Pelagatti, A. Vecchi, M. Rossi, S. Doselli, B. Farina, A. Olivani, G. Economopoulos, R. Dalla Valle, P. Fisicaro, C. Boni, G. Missale
Parma

52. Oncostatin M contributes to liver steatosis in experimental conditions of Metabolic dysfuntion Associated Steatotic Liver Disease
J. Nurcis, S. Sutti, I. Varriale, F. Protopapa, A. Provera, S. Cannito, B. Foglia, M. Maggiora, C. Bocca, E. Albano, M. Parola, E. Novo
Turin, Novara, Pavia

53. Long-term Bulevirtide monotherapy in patients with HDV-related compensated cirrhosis: effectiveness, safety and clinical outcomes from the retrospective multicenter european study (Save-D)
E. Degasperi, M.P. Anolli, M. Jachs, T. Reiberger, V. De Ledinghen, S. Metivier, G. D’Offizi, F. De Maria, C. Schramm, H. Schmidt, C. Zöllner, F. Tacke, C. Dietz-Fricke, H. Wedemeyer, M. Papatheodoridi, G. Papatheodoridis, I. Carey, K. Agarwal, F. Van Bömmel, M.R. Brunetto, M. Cardoso, G. Verucchi, A. Ciancio, F. Zoulim, S. Aleman, N. Semmo, A. Mangia, M.N. Hilleret, U. Merle, T. Santantonio, N. Coppola, A. Pellicelli, B. Roche, X. Causse, L. D’Alteroche, J. Dumortier, N. Ganne, F. Heluwaert, I. Ollivier, D. Roulot, M. Viganò, A. Loglio, A. Federico, F. Pileri, M. Maracci, M. Tonnini, J.P. Arpurt, K. Barange, E. Billaud, S. Pol, A. Gervais, A. Minello, I. Rosa, M. Puoti, P. Lampertico
Milan, Vienna (Austria), Bordeaux (France), Toulouse (France), Rome, Essen (Germany), Berlin (Germany), Hannover (Germany), Athens (Greece), London (UK), Leipzig (Germany), Pisa, Amadora (Portugal), Bologna, Turin, Lyon (France), Stockholm (Sweden), Bern (Switzerland), San Giovanni Rotondo (FG), Grenoble (France), Heidelberg (Germany), Foggia, Naples, Villejuif (France), Tours (France), Lyon (France), Bobigny (France), Annecy (France), Caen (France), Bergamo, Naples, Modena, Ancona, Bologna, Avignon (France), Toulouse (France), Nantes (France), Paris (France), Dijon (France), Créteil (France)

54. Autoimmunity in chronic HDV infection: results from the HDV Describe study cohort
G.P. Caviglia, E. Dileo, T. Manetta, B. Donati Marell, P. Merlach, A. Loglio, M. Viganò, S. Fagiuoli, P. Colombatto, B. Coco, A. Olivero, G. Troshina, A. Ciancio, D. Angrisani, G.G. Di Costanzo, C.F. Magni, S. Antinori, G. Rizzardini, V. Messina, M. Milella, A. Saracino, M. Quaranta, S. Taurian, C. Quarta, G. Cariti, V. Cossiga, F. Morisco, S. Cretella, G. Verucchi, E. Biliotti, A.R. Garbuglia, G. D’Offizi, R. Cotugno, M. Barone, R. Cozzolongo, E.M. Cela, E. Falbo, G.A. Niro, M. Feasi, E. Pontali, C. Coppola, R. Rapetti, M. Pirisi, N. Capoluongo, N. Cuomo, A. Perrella, A. Izzi, T.A. Santantonio, V. Di Marco, C. Cosentino, A. Marrone, M. Pisaturo, N. Coppola, G. Cologni, M. Rizzi, F. Barbaro, A.M. Cattelan, E. Fornasiere, P. Toniutto, M. Pallozzi, F.R. Ponziani, M. Dallio, M. Romeo, A. Federico, R. Viganò, L.S. Belli, L. Rapisarda, E. Siciliano, E. Bracciamà, A. Risicato, G. Bertino, M. Puoti, A. Civolani, M. Distefano, E. Teti, M. Andreoni, P. Anolli, P. Lampertico, T. Stroffolini, M.R. Brunetto, G. Mengozzi, M. Rizzetto
Turin, Bergamo, Milan, Pisa, Naples, Caserta, Bari, Bologna, Rome, San Giovanni Rotondo (FG), Castellana Grotte (BA), Foggia, Catanzaro, Lamezia Terme (CZ), Genoa, Gragnano (NA), Novara, Foggia, Palermo, Padua, Udine, Catania, Cagliari, Siracusa

55. Differential patterns of HBV RNA and HBcrAg levels in a large european cross-sectional study of untreated patients with chronic Hepatitis Delta
E. Degasperi, C. Scholtes, B. Testoni, S. Uceda Renteria, M.P. Anolli, C. Charre, F. Facchetti, M.L. Plissonnier, D. Sambarino, R. Perbellini, S. Monico, A. Callegaro, E. García-Pras, S. Lens, M.F. Cortese, X. Forns, S. Pérez-del-Pulgar, M. Heil, M. Levrero, F. Zoulim, P. Lampertico
Milan, Lyon (France), Paris (France), Barcelona (Spain), Pleasanton (USA), Rome

56. Diagnostic yield of whole exome sequencing in adult-onset cholestatic liver disease
M. Scaravaglio, L. Ronzoni, L. Cristoferi, L. Miano, E. Nofit, A. Gerussi, F. Malinverno, V. Moretti, V. Torcianti, C. Caime, M. Cadamuro, L. D’Antiga, P. Invernizzi, M. Carbone, L. Valenti
Milan, Monza, Bergamo

57. Prevalence and impact of Clinically Significant Portal Hypertension (CSPH) in patients with Hepatocellular Carcinoma (HCC): a multicenter cohort study on the ITA.LI.CA database
R. Chen, M. Dibetto Rimondini, E.G. Giannini, V. Santi, F. Pelizzaro, A. Sangiovanni, G. Cabibbo, F. Marra, F. G. Foschi, G. Svegliati Baroni, F.R. Ponziani, G. Missale, F. Morisco, R. Sacco, G. Ghittoni, C. Saitta, G. Vidili, F. Azzaroli, M.R. Brunetto, S. Boninsegna, D. Sacerdoti, G. Nardone, D. Magalotti, A. Mega, A. Martini, F. Tovoli, F. Piscaglia
Bologna, Genoa, Padua, Milan, Palermo, Florence, Faenza (RA), Ancona, Rome, Parma, Naples, Foggia, Viterbo, Messina, Sassari, Pisa, Negrar (VR), Verona, Bolzano

58. Ultrasound muscular thickness-based model to identify sarcopenia in patients with portal hypertension (PH): a cross-sectional single-center observational study
M. Lucà, G. Tosetti, V. Cardone, L. Argiento, S. Ridolfo, E. Acquati, F. Cicchetti, E. Xhepa, M. Pavan, P. Biondetti, A. Angileri, S. Stella, G. Carrafiello, P. Lampertico
Milan

59. Comparison of diagnostic performances of HDV RNA quantification assays used in clinical practice in Italy: data from the first national quality control multicenter study
L. Piermatteo, R. Salpini, G.P. Caviglia, A. Bertoli, M.R. Brunetto, B. Bruzzone, A. Callegaro, C. Caudai, D. Cavallone, L. Chessa, F. Coghe, N. Coppola, N. Cuomo, S. D’Anna, M. Di Stefano, F. Facchetti, C. Farina, D. Ferraro, E. Franchin, D. Francisci, S. Galli, A.R. Garbuglia, W. Gennari, V. Ghisetti, P. Lampertico, N. Marascio, S. Menzo, V. Micheli, G. Niro, A. Olivero, P. Paba, C.I. Palermo, O. Palmieri, S. Paolucci, M. Pisatur, T. Pollicino, G. Raffa, G. Torre, O. Turriziani, S. Uzzau, M. Vatteroni, M. Zazzi, A. Craxì, F. Ceccherini-Silberstein, V. Svicher on behalf of the Virology Italian Network Vironet C
Rome, Turin, Pisa, Genoa, Bergamo, Siena, Cagliari, Caserta, Naples, Foggia, Milan, Palermo, Padua, Perugia, Bologna, Modena, Turin, Catanzaro, Ancona, San Giovanni Rotondo (FG), Catania, Pavia, Messina, Sassari, Siena

60. Assessing portal hypertension with endoscopic ultrasound portal pressure gradient (eus-ppg): clinical correlations and procedural outcomes
F. Martini, L. Salvi, G. Scandali, C. Scorzoni, D. Balducci, M. Marzioni, L. Maroni, A. Benedetti, B. Moricoli, M.G. Danieli, D. Palmieri, A. Maolo, T. Piva, F. Marini, L.M. Daretti, E. Bendia, G. Tarantino
Ancona

61. Spatial transcriptomics maps the metabolic zonation of hepatocytes in MASLD I148M-PNPLA3 carriers
E. Paolini, M. Longo, M. Meroni, A.L. Fracanzani, P. Dongiovanni
Milan

62. Mapping the hepatic mtDNA genomic landscape in patients with MASLD: The Era of GPT-4 Artificial Intelligence
E. Paolini, M. Longo, M. Meroni, A. L. Fracanzani, P. Dongiovanni
Milan

63. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Italian women: s liver fibrosis independent from menopause?
R. Chen, A. Salamone, C. Abbati, R. Capelli, E. Santangeli, B. Stefanini, M.G. Indre, F. Ravaioli, F. Piscaglia, S. Ferri
Bologna

64. Prevalence and predictors of steatotic liver disease and significant liver fibrosis in an integrated hepatological and non-hepatological healthcare pathway model
A. Armandi, G.P. Caviglia, G. Beccuti, A. Andreis, F. Barutta, M. Bellettini, C. Rosso, A. Ferro, G. Bonacchi, K. Gjini, F. Amato, M. Marano, L. Vaira, M. Guariglia, E. Dileo, D. Castagno, G.M. De Ferrari, G. Alunni, M. Rinaldi, G. Gruden, E. Bugianesi
Turin

65. Liver transplants in untreated vs Bulevirtide-treated patients with chronic Hepatits Delta: a cross-sectional, intrahepatic analysis
E. Degasperi, C. Dibenedetto, M. Maggioni, D. Sambarino, F. Facchetti, M.P. Anolli, M. Sagasta, S. Monico, P. Toniutto, C. Zöllner, F. Tacke, N. Semmo, M.F. Donato, P. Lampertico
Milan, Udine, Berlin (Germany), Bern (Switzerland)

66. Similar Rates of Biochemical Response Are Observed Across Virologic Response Categories Over 96 Weeks of Bulevirtide Monotherapy in Patients With Chronic Hepatitis Delta
P. Lampertico, T. Asselah, V. Chulanov, P. Bogomolov, T. Stepanova, M. Cornberg, D. Manuilov, M. Li, A.H. Lau, B.L. Da, D. Tedesco, G.M. Chee, M.R. Brunetto, S. Zeuzem, F. Zoulim, H. Wedemeyer, S. Aleman
Milan, Clichy (France), Moscow (Russian Federation), Hannover (Germany), Foster City (USA), Pisa, Frankfurt am Main (Germany), Lyon (France), Stockholm (Sweden)

67. Anticoagulation in patients with liver cirrhosis and portal vein thrombosis
F. Cattazzo, M. Bevilacqua, L. De Marco, R. Stupia, A. Dalbeni, A. Mantovani, D. Ieluzzi, V. Paon, D. Sacerdoti
Verona

68. Prevalence of steatotic liver disease and steatohepatitis in a population of healthy workers
P. Guerra, J. Lopez Perez, S. Cagnin, P. Iruzubieta, P. Pontisso, M.L. Martínez-Chantar, A. Martini
Padua, Bilbao (Spain), Santander (Spain), Derio (Spain)

69. Efficacy and safety of BLV monotherapy for chronic hepatitis delta: posttreatment results through 48 weeks after the end of treatment from an interim analysis of a randomised Phase 3 study MYR301
S. Aleman, M. Brunetto, A. Blank, P. Andreone, P. Bogomolov, V. Chulanov, N. Mamonova, N. Geyvandova, V. Morozov, O. Sagalova, T. Stepanova, G.M. Chee, R.C. Mercier, A. Lichtman, D. Manuilov, S. Arterburn, A.H. Lau, A. Osinusi, F. Christian-Cox, F. Duff, J. Schulze zur Wiesch, M. Cornberg, S. Zeuzem, H. Wedemeyer, P. Lampertico
Stockholm (Sweden), Pisa, Heidelberg (Germany), Modena, Moscow (Russian Federation), Stavropol (Russian Federation), Samara (Russian Federation), Chelyabinsk (Russian Federation), Foster City (USA), Hamburg (Germany), Hannover (Germany), Frankfurt (Germany), Milan

70. The asymmetry of the liver and spleen stiffness measures between patients with chronic hepatitis B and D reflects clinic-pathologic differences
F. Damone, P. Colombatto, A. Pinna, G. Ricco,  D. Cavallone, G. Petralli, R. Vukotic, B. Coco,  L. Surace, V. Romagnoli, F. Oliveri, F. Bonino, M.R. Brunetto
Pisa, Naples

71. Impact of liver transplantation on spleen stiffness: early findings from a single-centre study
S. Ridolfo, C. Dibenedetto, V. Cardone, M. Sagasta, E. Sguazzini, B. Antonelli, L. Caccamo, M. Fraquelli, M.F. Donato, P. Lampertico
Milan

72. Patients with cirrhosis and ascites treated with long-term albumin: An integrated management proposal based on a real-life study
E. Pompili, G. Iannone, S. Piano, P. Toniutto, A. Lombardo, S. Gioia, G. Zaccherini, M. Tonon, R. Gagliardi, M. Baldassarre, G. Tedesco, L. Lani, V.  Guarneri, V. Di Marco, S. Nardelli, V. Calvaruso, D. Bitetto, P. Angeli, P. Caraceni
Bologna, Padua, Udine, Palermo, Rome

73. A dynamic contrast enhanced ultrasound based risk prediction model for the diagnosis of hepatocellular carcinoma in the grey area of ceus li-rads: The person4 model
L. Galasso, G. Esposto, P. Santini, I. Mignini,  R. Borriello, M.E. Ainora, A. Gasbarrini, M.A. Zocco
Rome

74. Quantification of plasma HDV RNA in untreated and Bulevirtide-treated patients with CHD: a comparison between Robogene 2.0, Eurobioplex EBX071 and Altostar
M.P. Anolli, S. Uceda Renteria, E. Degasperi, F. Facchetti, D. Sambarino, M. Borghi, R. Perbellini, R. Soffredini, S. Monico, A. Callegaro, P. Lampertico
Milan

75. An easy and reproducible strategy to improve the structural integrity of the albumin molecule in commercial vials
M. Baldassarre, M. Naldi, G. Zaccherini, E. Pompili, G. Iannone, D. Tedesco, M. Nugnes, E. Fabini, K. Pock, G. Tedesco, O. Hegener, M. Bartolini, P. Caraceni
Bologna, Vienna (Austria)

76. Outcome of hepatic resection for hepatocellular carcinoma in ideal and non-ideal candidates
L. Lani, L. Bucci, V. Santi, B. Stefanini, B. Stefanini, A. Sangiovanni, S. Grasselli, G. Ghittoni, C. Saitta, F. Morisco, G. Cabibbo, F. Marra, G. Vidili, M.R. Brunetto, F.G. Foschi, M. Di Marco, G. Svegliati Baroni, F. Pelizzaro, F. Azzaroli, F.R. Ponziani18, A. Martini, D. Sacerdoti, A. Mega, S. Boninsegna, E.G. Giannini, D. Magalotti, R. Sacco, G. Nardone, A. Vitale, F. Trevisani for the Italian Liver Cancer (ITA.LI.CA) group
Bologna, Milan, Parma, Viterbo, Messina, Naples, Palermo, Florence, Sassari, Pisa, Faenza (RA), Bergamo, Ancona, Padua, Rome, Verona, Bolzano, Negrar (VR), Genoa, Foggia, Naples

77. The svr10k study: a real-world data with pangenotypic direct-acting antivirals across multiple diverse regions
G. Lai-Hung Wong, M.R. Alvares-da-Silva, F. Higuera-de-la-Tijera, M. Lung Yu, S. Aleman, J. Garcia-Samaniego, J. Cabezas, M. Casado, M. Alzaabi, A. Chandak, M. Martínez, A. Khachatryan, L. Chen, C. Hernandez, Y. Jun Wong
Hong Kong, Porto Alegre (Brazil), Ciudad de Mexico (Mexico), Kaohsiung (Taiwan), Stockholm (Sweden), La Paz (Spain), Valdecilla (Spain), Torrecárdenas (Spain), Abu Dhabi (UAE), Radnor (USA), Foster City (USA), Singapore

78. Systolic and diastolic dysfunction, but not cardiac hyper-contractility, are unrelated to liver disease severity: a multicentric cohort study
M. Bevilacqua, F. Cattazzo, S. Romano, A. Dalbeni, R. Stupia, L. De Marco, D. Ieluzzi, V. Paon, A. Comuzzi, A. Marca, R. Villani, R. Lombardi, A. Salzano, D. Sacerdoti
Verona, Foggia, Milan, Naples

79. Carriage of rare pathogenic apob variants predispose to severe MASLD and HCC
M. Mureddu, S. Pelusi, O. Jamialahmadi, G. Periti, L. Ronzoni, H. Heigadeh, F. Malvestiti, M. Saracino, V. Moretti, V. La Mura, R. D’Ambrosio, S. Petta, A.L. Fracanzani, L. Miele, U. Vespasiani Gentilucci, E. Bugianesi, D. Prati, C.V. Schneider, S. Romeo, L.V.C. Valenti
Milan, Gothenburg (Sweden), Pavia, Palermo, Rome, Turin, Aachen (Germany), Catanzaro, Stockholm (Sweden)

80. Outcomes of patients with alcohol-related cirrhosis referred to a hepatology outpatient clinic
G. Iannone, D. Pratelli, E. Pompili, C. Di Stefano, M. M. Bossi, M. Manno, M. Baldassarre, V. Guarneri, G. Tedesco, S. Lorenzini, P. Caraceni, G. Zaccherini
Bologna

81. Use of proton pump inhibitors among German Hepatitis C patients treated with sofosbuvir/velpatasvir: data from the German hepatitis C-Registry (2016–2022)
M. Cornberg, G. Teuber, R. Link, U. Naumann, H. Klinker, C. John, C. Hernandez, M. Schwenken, C. Sarrazin
Hannover (Germany), Frankfurt am Main (Germany), Offenburg (Germany), Berlin (Germany), Würzburg (Germany), Berlin (Germany), Uxbridge (UK), Madrid (Spain), Munich (Germany), Wiesbaden (Germany)

82. Atezolizumab plus Bevacizumab does not cause subclinical cardiotoxicity evaluated by Left-Ventricular Global Longitudinal Strain
M. Bevilacqua, R. Calzamatta, R. Stupia, S. Romano, F. Cattazzo, A. Dalbeni, L. De Marco, D. Ieluzzi, V. Paon, D. Sacerdoti
Verona

83. Liver and spleen stiffness measure by transient elastograghy: a promising tool for the clinical management of patients after Fontan-type surgery circulation
B. Coco, L. Ait Ali, G. Petralli, L. De Stefano, P. Colombatto, R. Vukotic, A. Salvati, F. Bonino, P. Festa, M.R. Brunetto
Pisa, Massa, Naples

84. Use of Glucagon-like Peptide-1 Receptor Agonist is associated with reduced risk of major liver-related events: a meta-analysis
C. Celsa, G. Pennisi, A. Tulone, G. Ciancimino, M. Vaccaro, G. Di Maria, G. Infantino, M. Enea, C. Cammà, S. Petta
Palermo

85. Skin injuries prevention during TIPS creation: use of “alert levels” and “trigger levels” in a high volume TIPS referral hospital (20 procedures/year)
C.M. Giacchetto, B. Magro, L. Marruzzelli, A. Galante, R. Miraglia
Palermo

86. The relationship between serum bile acids and event-free survival following the use of maralixibat for progressive familial intrahepatic cholestasis: data from MARCH/MARCH-ON
L. D’Antiga, R.J. Thompson, S.P. Horslen, D.B. Mogul, T. Nunes, W. Garner, P. Vig, A.G. Miethke
Bergamo, London (UK), Pittsburgh (USA), Foster City (USA), Cincinnati (USA)

87. Characterization of transcriptional and functional CD8 T cell heterogeneity to design individualized correction strategies for chronic HBV infection
M. Rossi, A. Vecchi, F. Guerrieri, C. Tiezzi, M.L. Plissonnier, E. Degasperi, D. Sambarino, P. Fisicaro, E.A. Gabor, S. Doselli, B. Farina, G. Missale, P. Lampertico, C. Ferrari, M. Levrero, C. Boni
Parma, Lyon (France), Milan, Rome

88. Assessing perilipin-2 as a liver-specific biomarker: lack of correlation between cardiac damage and its levels in heart failure patients
L. Petrucci, G. Angelini, I. Fumarulo, S. Russo, A. Liguori, M. Vaccarella, B. Garramone, M. Massetti, A. Gasbarrini, G. Mingrone, N. Aspromonte, L. Miele
Rome

89. Clinical benefits of maralixibat for patients with Alagille syndrome are durable through 7 years of treatment: data from the MERGE study
D.A. Kelly, B.M. Kamath, E. Gonzales, K.F. Murray, D.H. Leung, D.B. Mogul, A. Soglian, W. Garner, P. Vig, E. Jacquemin
Birmingham (UK), Philadelphia (USA), Toronto (Canada), Paris (France), Cleveland (USA), Houston (USA), Foster City (USA)

90. Gaps in metabolic dysfunction-associated steatotic liver disease (MASLD) screening and management: a retrospective audit of patients at cardiometabolic risk in secondary care
M. Cucco, R. De Maria, C. Pavanello, L. Cesarini, G. Mombelli, A. Alberti, F. Bertuzzi, L. S. Belli, L. Calabresi
Milan

91. Liver disease is highly prevalent in patients with hereditary transthyretin-related amyloidosis
C. Pitrone, R. Filomia, M.S. Franzè, M. Barresi, G. Caccamo, P. Liotta, L. Teresi, M. De Luca, M. Russo, A. Mazzeo, I. Cacciola, G. Di Bella, C. Saitta
Messina

92. Relationship between recipient/donor features and liver stiffness measurement in the first year after liver transplantation
C. Dibenedetto, E. Sguazzini , M. Sagasta, L. Caccamo, B. Antonelli , M.F. Donato, P. Lampertico
Milan

93. Bone fragility and fracture risk assessment in metabolic disfunction-associated steatotic liver disease
C. Asero, C. Oliveri, M.S. Franzé, A. Di Giovanni, R. Filomia, G. Caccamo, C. Pitrone, C. Saitta, C. Morace, N. Morabito, G. Basile, A. Catalano, I. Cacciola
Messina

94. Direct effects of psilocybin on serotonin receptors regulate lipid accumulation in hepatic cells and adipocytes
A. Signor, M. Colognesi, D. Gabbia, I. Zanotto, Y. Frion-Herrera, S. Comai, A. Mattarei, G. Pasut, F. Folli, M. Pappagallo, P. Manfredi, S. De Martin
Padua, Milan, Coral Gables (USA)

95. Beneficial effect of the combination psilocybin-semaglutide in a murine model of Steatotic Liver Disease
M. Colognesi, D. Gabbia, A. Signor, S. Comai, A. Mattarei, G. Pasut, F. Folli, L. Centofanti, S. La Rosa, G. Finzi, M. Pappagallo, P. Manfredi, S. De Martin
Padua, Milan, Varese, Coral Gables (USA)

96. Outcome and predictors of major adverse cardiovascular events after liver transplantation: a single center experience
E.V. Pesatori, L. Pasulo, M. Viganò, F. Leonardi, A. Rossi, S. Camagni, F. Neri, A. Loglio, D. Pinelli, S. Fagiuoli
Bergamo, Milan

97. Improving effects of sacubitril/valsartan on hepatic fibrosis in MASLD patients with heart failure
G. Fabris, L. Portolan, M. Zoncapè, L.A. Natola, D. Sacerdoti, A.Piccoli, A. Dalbeni
Verona

98. A multicenter analysis on efficacy and safety of Tenofovir alafenamide (TAF) in a wide cohort of patients with chronic hepatitis B (CHB)
M. Tizzani, G.P. Caviglia, A. Frasson, E. Degasperi, M. Viganò, M. Borghi, D. Sambarino, A. Loglio, E. Farina, S. Fagiuoli, P. Lampertico, A. Marzano
Turin, Milan, Bergamo

99. Prognostic value of liver stiffness trends vs. absolute values after sustained virological response in HCV-related advanced chronic liver disease. A monocentric retrospective study
F. Cerini, J. Schropp, A. Cosenza, C. Selvaggio, C. Masellis, M. Rumi, A. Berzigotti
Milan, Bern (Switzerland)

100. Epidemiologic features influencing the selection of direct acting antivirals (DAA) in HCV patients: an Italian real-world study
N. Pugliese, F. Conti, V. Rosato, P. Gallo, S. Gitto, F. Frigerio, V. Perrone, C. Veronesi, M. Cappuccilli, L. Degli Esposti, M. Riglietta, A. Mangia
Rozzano (MI), Faenza (RA), Naples, Rome, Florence, Milan, Bologna, Bergamo, S. Giovanni Rotondo (FG)

101. Pathogenic pathways in MASLD: comparison between “Metabolic” and “Genetic” MASLD, a multiOmics cohort study
P. Torre, B.M. Motta, M. Lombardi, T. Sarcina, R. Coppola, M. Festa, J. Troisi, M. Masarone,  M. Persico
Baronissi (SA), Montecorvino Pugliano (SA)

102. Outcomes of HBV and HCV testing in Italy’s marginalized communities: a step towards WHO plan to end viral hepatitis as a public health threat by 2030
I. De Giorgi, M. Monti, T.Caruso, A. Castellaccio, G. Cavallini, M.L. Manca, S. Lorini, S. Marri, L. Petraccia , F. Madia, C. Stasi, L.Carraresi, E. Lorefice, S.I. Bonelli, A. Nerli, L. Martini, S. Gitto, D. Aquilini, P. Blanc, A.L. Zignego, L. Gragnani
Florence, Pisa, Pistoia, Rome, Siena, Empoli (FI), Prato

103. Exploring the interplay between sarcopenia, liver and cardiovascular damage in non-cirrhotic MASLD patients: a genetic perspective
F. Alletto, A. Cespiati, R. Lombardi, F. Santomenna, G. Pisano, G. Oberti, C. Bertelli, R. Forlano, P. Manousou, P. Dongiovanni, A.L. Fracanzani
Milan, London (UK)

104. Prognostic implications of minimal serum creatinine fluctuations in acutely decompensated cirrhosis
M. Botta, M. Tizzani, A. Calleri, C. Lisi, G. Pecorella, M. L. Robone, M. Bonomo, E. Bertoldi, F. Frigo, D. Campion, A. Ottobrelli, A. Marzano, E. Bugianesi, G. M. Saracco, C. Alessandria
Turin

105. Baseline liver elastography and its longitudinal changes predict liver related outcomes in patients with Metabolic dysfunction Associated Steatotic Liver Disease (MASLD)
A. Liguori, L. Petrucci, F. Pantaleo, F.S.M. Youssef, G. Marrone, M. Biolato, M. Pompili, A. Grieco, A. Gasbarrini, L. Miele
Rome

106. Coagulation imbalance is associated with hepatic and vascular complications in patients with MASLD and diabetes: key role of factor VIII
R. Lombardi
Milan, London (UK), Tricase (LE)  

107. MiR-22-3p targets the G2/M checkpoint inhibitor Wee1 and represents a possible biomarker of TACE response in hepatocellular carcinoma
G. Galvani, C. Vianello, I. Leoni, E. Monti, G. Marisi, A. Casadei Gardini, G.F. Foschi, M.L. Lazzari, C. Giovannini, G. Ravegnini, I. Salamon, M. Ferracin, F. Piscaglia, M. Negrini, C. Stefanelli, D. Trerè, L. Gramantieri, F. Fornari
Rimini, Meldola (FC), Milan, Faenza (RA), Bologna, Ferrara

108. Prevalence and influence of diabetes mellitus on clinical outcomes in patients hospitalized for acutely decompensated cirrhosis
M. Bonomo, A. Calleri, M. Tizzani, C. Lisi, G. Pecorella, M. L. Robone, M. Botta, F. Frigo, D. Campion, A. Ottobrelli, A. Marzano, E. Bugianesi, G.M. Saracco, C. Alessandria
Turin

109. Checkpoint inhibitor-induced liver injury (ChILI) in patients with advanced skin cancer: a single center experience
A. Liguori, S. Archilei, M. Salvi, G. Marrone, M. Biolato, L. Miele, M. Pompili, A. Di Stefani, K. Peris, A. Gasbarrini, A. Grieco
Rome

110. Rectus femoris cross sectional area predicts 90-day readmission in patients hospitalized for an acute decompensation of cirrhosis
R. Gagliardi, P. Campadello, S. Brocco, S. Incicco, V. Calvino, B. Sikadi, M. Tonon, A. Brocca, C.G. Gambino, N. Zeni, G. De Conti, C. Giraudo, P. Angeli, S. Piano
Padua

111. Determinants of liver stiffness measurements changes in Metabolic dysfunction-Associated Steatotic Liver Disease: insights from two cohorts
M. Zoncapè, A. Liguori, S. Pelusi, C. Bianco, D. Roccarina, L. Iogna Prat, A. Mantovani, J. Clancy, A. Goyale, L. Valenti, E.A. Tsochatzis
London (UK), Verona, Rome, Milan

112. Liver stiffness measurement by SuperSonic Imagine two-dimensional shear wave elastography to predict hepatocellular carcinoma in non-cirrhotic metabolic dysfunction-associated steatotic liver disease
M.G. Indre, B. Stefanini, C. Abbati, M. Boe, R. Cappelli, R. Chen, E. Santangeli, F. Tovoli, M.C. Morelli, F. Piscaglia, S. Ferri, F. Ravaioli
Bologna

113. A peculiar composition of HBsAg isoforms characterizes chronic HDV coinfection respect to HBV mono-infection with higher middle – and large – HBs levels reflecting a more intense HDV activity
A. Magnapera, L. Piermatteo, S. D’Anna, A. Olivero, L. Duca, G. Torre, C. Castelli, E. Teti, A. Di Lorenzo, V. Malagnino, M. Iannetta, L. Baiocchi, S. Francioso, I. Lenci, F. Ceccherini-Silberstein, M. Milella, A. Saracino, A. Ciancio, L. Sarmati, P. Lampertico, M. Rizzetto, G.P. Caviglia, V. Svicher, R. Salpini
Rome, Turin, Bari, Milan

114. Evaluation of the intratumoral immune microenvironment in hepatocellular carcinoma treated with liver surgery after selective internal radiation therapy
M.S. Franzè, H. Dahboul, A. Beaufrère, M. Bouattour, M. Lesurtel, M. Ronot, V. Paradis, A. Luciani, H. Kobeiter, D. Sommacale, V. Leroy, R. Brustia, H. Regnault, J. Calderaro, G. Amaddeo
Créteil (France), Messina, Clichy (France)

115. Cardiopulmonary hemodynamics and liver stiffness changes in predicting cardiac decompensation after TIPS: a prospective study
D. Saltini, T. Guasconi, C. Caporali, M. Bianchini, F. Casari, F. Prampolini, B. Lei, M. Scoppettuolo, F. Ascari, A.S. Velasco Mayorga, A. Piscopo, A. Colecchia, F. Schepis
Modena

116. The impact of first and further decompensation in patients with metabolic-dysfunction associated compensated advanced chronic liver disease
G. Pennisi, G. Di Maria, V.W.S. Wong, V. de Ledinghen, G. Sebastiani, M. Viganò, A.L. Fracanzani, L. Miele, E. Bugianesi, M. Ekstedt, R. D’Ambrosio, F. Ravaioli, F. Schepis, F. Marra, A.M. Aghemo, G. Svegliati Baroni, M. Persico, L. Valenti, A. Berzigotti, J. George, A. Armandi, P. Nasr, S. Kechagias, D. Saltini, Y.P. Mendoza, V. Calvaruso, M. Enea, H. Lin, G. Infantino, M. Masarone, N. Pugliese, A. Tulone, V. Di Marco, C. Cammà, S. Petta
Palermo, Hong Kong, Pessac (France), Montreal (Canada), Milan, Rome, Turin, Linköping (Sweden), Bologna, Modena, Florence, Rozzano (MI), Ancona, Salerno, Bern (Switzerland), Sydney (Australia)

117. Our Hub Hospital experience with adult liver transplantation referral in hepatic cirrhosis
E. Garlatti Costa, E. Fornasiere, S. Fumagalli, E. Fumolo, A. Ferrarese, G. Dettori, S. Venturini, D. Bitetto, G. Germani, P. Toniutto, P. Burra, S. Grazioli
Pordenone, Udine, Padua

118. Prevalence and clinical impact of rectal colonization by multidrug-resistant (MDR) bacteria in patients with acute decompensation of cirrhosis
N. Zeni, J. Bañares, M. La Franca, S. Incicco, R. Gagliardi, A. Barone, A. Accetta, V. Calvino, G. Antonacci, A. Romano, C. Gambino, M. Tonon, P. Angeli, S. Piano
Padua, Barcelona (Spain)

119. More advanced presentation but similar survival for hepatocellular carcinoma in HIV positive compared to HIV-negative patients: a retrospective cohort analysis
M. Iavarone, E. Alimenti, M. Puoti, H. Hasson, B. Monti, F. Peracchi, A. Siribelli, M. Fava, M. Bruccoleri, M. Merli, G. Morsica, A. De Silvestri, P. Bonfanti, A. Castagna, A. Soria, P. Lampertico
Milan, Monza, Pavia

120. Clinical characterization and evolution of disease in a large cohort of 196 patient with autoimmune hepatitis in a referral center
S. Vavassori, F. Samartin, C. Limosani, L. Pastorelli, A.L. Crosignani, E. Bertolini, P.M. Battezzati
Milan

121. Assessment of response and impact of safety treatment with bulevirtide in patients with chronic delta virus infection: an observational trial for evaluating long-term efficacy. the ARISTOTELE pilot study
L. Rinaldi, M. Viganò, V. Messina, A. Caturano, G. Niro, N. Capoluongo, A. Loglio, L. Marinaro, A. Marrone, E. Claar, M. Russello, E. Ciracì, U. Vespasiani Gentilucci, A. Ciancio, V. Pace Palitti, C. Acierno, A. Mormone, R. Cotugno, F. Terracciani, P. Gallo, M.R. Cannavò, V. Rosato, F. Benanti, P. Cariti, E. Falbo, M. di Stefano, R. Sacco, A. Perrella, A. Izzi
Campobasso, Bergamo, Caserta, Naples, San Giovanni Rotondo (FG), Turin, Catania, Ostuni (BR), Rome, Pescara, Potenza, Catania, Lamezia Terme (CZ), Siracusa, Foggia

122. Outcomes of durvalumab with or without tremelimumab in routine clinical practice according to HIMALAYA Trial Eligibility: preliminary results of the international DT-real study
C. Celsa, N. Nishida, S.M. Chamseddine, A. Arvind, M. Li, H. Toyoda, S. Ulahannan, C.A.M. Fulgenzi, G.F. Manfredi, A. D’Alessio, B. Stefanini, G. Cabibbo, C. Cammà, B. Scheiner, L. Rimassa, R.K. Kelley, A.G. Singal, A.O. Kaseb, M. Kudo, D.J. Pinato
London (UK), Palermo, Osaka (Japan), Houston (USA), Dallas (USA), San Francisco (USA), Gifu (Japan), Oklahoma City (USA), Novara, Bologna, Vienna (Austria), Pieve Emanuele (MI), Rozzano (MI)

123. Multiparametric ultrasound for the prediction of the outcomes of endoscopic variceal band ligation
R. Borriello, V. Calvez, G. Esposto, I. Mignini, M.E. Ainora, L. Galasso, A. Gasbarrini, M.A. Zocco
Rome

124. The prognostic role of LiverRisk score in patients with compensated cirrhosis
M. Tonon, A. Accetta, S. Incicco, R. Gagliardi, N. Zeni, V. Santori, V. Calvino, G. Antonacci, C.G. Gambino, S. Piano
Padua

125. Survey on acute on chronic liver failure in internal medicine departments and transplant centers of Lazio
M. Delle Monache, M. Carli, C. Conigliani, F. Pascucci, G.M. Ettorre, N. Guglielmo, L. Baiocchi, I. Lenci, Q. Lai, V. Ramundo, C. Ripani, S. Furfaro, A. Cappelli and Area Epatologica FADOI Lazio
Rome

126. The changing scenario in hepatocellular carcinoma management: the Niguarda experience
C. Mazzarelli, R. Viganò, G. Perricone, L. Cesarini, A. Airoldi, M. Vangeli, M. Carbone, C. Becchetti, M. Cucco, R. Stigliano, F. Aprile,  G. Dispenzeri, A. Lauterio, I. Mangoni, V. Buscemi, F. Ferla , A. Mariani, G. Checchini, R. De Carlis,  L. Centonze, R. Cerchione, F. Morelli,  A. Alfonsi, P. Brambillasca, F. Villa, K. Bencardino,  A. Vanzulli, C. Sgrazzutti,  I. Vicentin, M. Palazzi, D. Sibio, C. Rossetti, G. Cabrini, S. Capitanio, M. Solcia, L.G. De Carlis, L.S. Belli
Milan

127. Safety considerations for finite nucleos(t)ide analogue (NA) in Chronic Hepatitis B infection, a single-center, observational and restrospective study
M. Calia, E. Asperges, V. Zuccaro, L. Maiocchi, S. Paolo, R. Bruno
Pavia

128. Non invasive tests to rule out clinical significant portal hypertension and high- risk varices in autoimmune hepatitis
A. Gerussi, A. Bonfichi, L. Capodicasa, G. Di Maria, L. Cristoferi, F. Malinverno, M.C. Neglia, C. Celsa, M. Carbone, A. Di Sabatino, P. Invernizzi, V. Calvaruso
Monza, Pavia, Palermo, Milan

129. Longitudinal analysis of viral profiles in chronic HBV/HDV coinfected patients
C. Musolino, V. Chines, D. Lombardo, D. Giosa, S. Franzè, G. Raffa, D. Ferraro, I. Cacciola, V. Di Marco, G. Raimondo, T. Pollicino
Messina, Palermo

130. Etiology-specific Coronary Artery Calcium Score thresholds for cardiovascular risk stratification in liver transplant candidates
N. Sperduti, C. Telesca, S. Demma, D. Cartoni, A. Pingitore, V. Buffa, A. Pellicelli, G.M. Ettorre, V. Giannelli
Rome

131. Alkaline Phosphatase Changes With Seladelpar Across Subgroups Of Primary Biliary Cholangitis Patients In The Response Trial
K. Kowdley, K. Yimam, S. Kumar, E. Mena, A. Bonder, K. Gautham Reddy, C. Corpechot, S. Carroll, F. Frigerio, K. Yang, D.B. Crittenden, C. McWherter
Seattle (USA), San Francisco (USA), New York (USA), Pasadena (USA), Boston (USA), Chicago (USA), Paris (France), Foster City (USA), Fremont (USA)  

132. Long-Term Efficacy and Safety of Open-Label Seladelpar Treatment in Patients With Primary Biliary Cholangitis: Pooled Interim Results for up to 3 Years From the ASSURE Study
E.J. Lawitz, P.J. Trivedi, K. V. Kowdley, S.C. Gordon, C.L. Bowlus, M.C. Londoño, G.M. Hirschfield, A. Gulamhusein, D.B. Crittenden, F. Frigerio, S. Zhuo, C. Heusner, C. Levy
San Antonio (USA), Birmingham (UK), Seattle (USA), Detroit (USA), Sacramento (USA), Barcelona (Spain), Toronto (Canada), Foster City (USA), Fremont (USA), Miami (USA)

133. At the boundaries: analyzing short and long-term outcome after paediatric liver transplantation: Padua experience
A. Ferrarese, M. Cananzi, L. Bosa, A. Dolcet, M. Senzolo, F.P. Russo, G. Germani, M. Gambato, A. Zanetto, E. Catanzaro, M. Grasso, F. D’Arcangelo, M.L. Vivian, E. Gringeri, U. Cillo, P. Burra
Padua

134. A proof of concept study evaluating the role of lipopolysaccharide-induced tumor necrosis factor in hepatocellular carcinoma
R. Piciotti, F. Tiano, N. Panera, M. Bianchi, N. Cicolani, A. Alisi
Rome

135. The devastating impact of severe pruritus in primary biliary cholangitis
H.T. Smith, M.M. McLaughlin, S. Das, A. Ribeiro, P. Andreone, P. J.F. Trok, A. E Kremer, D. Jones
London (UK), Collegeville (USA), Hyderabad (India), Madrid (Spain), Baggiovara (MO), Zürich (Switzerland), Newcastle (UK)

136. Domino liver transplantation from an adult patient with propionic acidemia: a case report of the first documented case worldwide
M. Stecchi, F. Mirici Cappa, V. Vero, R. Di Donato, A. Baldan, M.C. Morelli, M. Cescon, P. Pianta, L. Brodosi
Bologna

Per iscriversi all’evento clicca qui:

NUOVI SOCI AISF
Per accedere in qualità di Socio AISF all’Evento Formativo è necessario iscriversi all’Associazione cliccando qui:  

L’iscrizione all’AISFdà diritto alla partecipazione gratuita alle Riunioni Istituzionali “Riunione Generale Annuale”, “Riunione Monotematica” e “Special Conference”, all’abbonamento gratuito alla rivista Digestive and Liver Disease ed a ricevere qualsiasi informazione relativa all’attività dell’Associazione.

NON SOCI AISF
€ 300,00 (inclusa IVA 22%)
Le quote di iscrizione includono: l’accesso alle Sessioni Scientifiche, coffee breaks, lunches, l’attestato di partecipazione, l’attestato E.C.M. (se conseguito).
Per iscriversi all’evento clicca qui:

Termine per Iscrizione all’Annual Meeting: 28 Febbraio 2025

Al termine dell’iscrizione, riceverete un e-badge via e-mail. Vi preghiamo di conservarlo sul vostro smartphone e, in sede di evento, scansionare il QR code presente sull’e-badge ai terminali self-service nella zona di benvenuto e stampare quindi il badge di accesso ai lavori congressuali. Il Pre Meeting e l’Annual Meeting prevedono due distinti e-badge di registrazione.

Cancellazione e rimborsi
Le cancellazioni pervenute entro il giorno 28 Febbraio 2025, tramite comunicazione scritta alla Segreteria Organizzativa, daranno diritto ad un rimborso totale dell’importo versato, adetratto l’importo di € 15,00 per spese amministrative.
Superata tale data non saranno riconosciuti rimborsi. I rimborsi saranno effettuati solo dopo il termine dell’Evento.